The Latest "Buzz on the Street" Show: Featuring Pressure Biosciences (OTCQB: PBIO) BaroShear Sale | Financial Buzz

The Latest “Buzz on the Street” Show: Featuring Pressure Biosciences (OTCQB: PBIO) BaroShear Sale’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Pressure BioSciences Announces First Close and Customer for its Revolutionary Water-Soluble CBD Manufacturing System, the BaroShear K45.”

Pressure BioSciences, Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, announced the initial sale of its revolutionary BaroShear K45 processing system. This novel instrument system is based on the Companys proprietary Ultra Shear Technology platform. The BaroShear K45 is a unique and powerful nanoemulsification system designed to resolve one of the most critical problems facing CBD manufacturers today: the extremely poor water solubility of CBD Oil.

Pressure BioSciences, Inc. is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant and alternating hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions.

Almost every year, a contagious outbreak occurs in various regions around the world. In efforts to mitigate their spread, health officials mandate that citizens receive vaccinations. However, despite the immediate access to healthcare in many regions, people are still widely affected by these diseases. For instance, the Democratic Republic of the Congo has been experiencing a massive Ebola outbreak which ultimately led the World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus to declare the Ebola outbreak a public health emergency of international concern. Additionally, the Ebola outbreak can potentially spread across to other global regions. For instance, in 2014, a major Ebola outbreak occurred in the African subcontinent and a traveler flying out of Africa spread the disease to the U.S., causing a public health scare. For these reasons, when global outbreaks like the Ebola epidemic occur, health officials around the world often take extensive measures. For instance, the Centers for Disease Control and Prevention sets up exit screenings at the originating country and then an entry screening at the destination. While screenings can be effective, there is still a chance that the disease can spread and as a result, medical institutions and officials need to be prepared. Moreover, the U.S. experienced its largest measles outbreak earlier in 2019, affecting a reported 695 people. However, officials were able to limit the number of deaths due to immunizations and vaccines. Overall, the occurrence of these outbreaks has led many biotechnology companies to accelerate their pipelines and develop more effective treatments. According to data compiled by Global Market Insights, the global biotechnology market was valued at USD 399.4 Billion in 2017. Additionally, by 2024, the market is forecast to surpass USD 775 Billion while registering a CAGR of 9.9% from 2018 to 2024. 

While these outbreaks are a major public concern, there is also a large demand for therapies and drugs to treat cases that aren’t contagious. Specifically, conditions such as cancer, autoimmunity/inflammation, infectious agents, and genetic disorders impact a significant number of people each year. In particular, cancer has a huge impact on society in the U.S. and across the world. In 2018, it was estimated that 1.73 million people were diagnosed with cancer and 609,640 people died from the disease, according to the National Cancer Institute. Generally, for cancer cases, many patients receive treatments such as chemotherapy or radiotherapy to either make the cancer cells dormant or eliminate them. Notably, an emerging treatment for cancer is targeted therapy. While chemotherapy and targeted therapy both use drugs, targeted therapy is different because it specifically targets the cancer’s particular genes, proteins, and environment that aid in its spread and survival. However, chemotherapy can have serious side effects such as damaging cells in the bone marrow, hair follicles, and cells in the mouth, digestive tract, and reproductive system, leading to severe side effects. Nevertheless, biotechnology companies have aimed to develop innovative treatments that are much safer while maintaining their efficiency. In particular, therapeutic proteins have emerged because of its advantages over traditional treatments. For example, therapeutic proteins are a highly specific and complex set of functions that are less likely to interfere with normal biological processes and cause adverse effects, according to Creative Biolabs. Moreover, therapeutic proteins are well tolerated and less likely to cause immune responses. Additionally, certain protein-based drugs can control the growth and activity of immune cells and help boost your immune system to prevent cancer. “Today new avenues for cancer diagnostics and therapeutics present themselves. The choices include specific diagnostics, such as the rapidly evolving use of liquid biopsies that analyze cells and molecules spawned by the tumor and found in bodily fluids such as blood or urine, a more focused analysis of non-responders, the financial implications of future therapies, and an advocacy for a return to basic scientific research. The result of exploring these options will be a wider range of treatment choices for oncologists and a more positive outcome for patients,” said Steve Brozak, President of WBB Securities, LLC, an investment bank and research firm that specializes in the biotechnology, specialty pharmaceutical and medical device sectors.

For more information, please visit: Pressure Biosciences, Inc.

For more corporate news on Pressure Biosciences Inc., check out the Buzz on the Street

About Buzz on the Street: One of’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pressure biosciences, inc, financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: